Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	1.20T
Revenue (ttm)	1.20T
Net Income (ttm)	-116.55B
Shares Out	79.35M
EPS (ttm)	-1,880.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,296,370
Average Volume	455,053
Open	14,640
Previous Close	14,890
Day's Range	13,700 - 15,420
52-Week Range	9,260 - 15,990
Beta	0.37
RSI	60.52
Earnings Date	Mar 20, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.